The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: A phase 1a study

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 28, Issue 3, 2014, Pages 216-225

  Eisenberg, Elon ^a,b   Ogintz, Miri ^c   Almog, Shlomo ^d,e  

^a Institute of Pain Medicine   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Rambam Medical Centre   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Analgesia; Inhalation; Medicinal cannabis; Neuropathic pain; Pain; Pharmacokinetics; Vaporization

Indexed keywords

11 HYDROXYDRONABINOL; CANNABIS; TETRAHYDROCANNABINOL; DRONABINOL; MEDICAL CANNABIS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; RADICULOPATHY; SPINAL CORD INJURY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; BLOOD; CHRONIC PAIN; CLINICAL TRIAL; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT;

ADULT; AGED; CHRONIC PAIN; DRONABINOL; FEMALE; HUMANS; MALE; MEDICAL MARIJUANA; METERED DOSE INHALERS; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84906805852     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2014.941130     Document Type: Article

References (32)

1. Rog DJ, Nurmikko Tj, Friede T, Young CA. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology. 2005;65: 812-819.
2. Wade DT, Makela PM,House H, Bateman C, Robson P. Longterm use of a cannabis based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12:639-645.
3. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-1132.
4. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebocontrolled trial. CMAJ. 2012; 184:1143-1150.
5. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebocontrolled trial. Neurology. 2007;68:515-521.
6. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.
7. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21-29.
8. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double blind, placebo-controlled clinical trial. Pain. 2007;133:210-220.
9. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neurophatic pain. J Pain. 2008;9:506-521.
10. Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improved neuropathic pain. J Pain. 2013;14:136-148.
11. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ. 2010;182:E694-E701.
12. Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. Themedicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199-210.
13. Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetrahydrocannabinol concetrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409-416.
14. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral δ9- tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57:66-75.
15. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327-360.
16. Huestis MA. Human cannabinoid pharmacokinetics. Chemistry and drug metabolism. Chem Biodivers. 2007;4:1770-1804.
17. Gieringer DH. Cannabis "vaporization": A promising strategy for smoke harms reduction. J Cannabis Ther. 2001;1:153-170.
18. Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004;4:7-27.
19. Abrams DI, Vizoso HP, Shade SB, et al. Vaporization as a smokeless cannabis delivery system: A pilot study. Clin Pharmacol Ther. 2007;82:572-578.
20. United Nations Office of Drugs and Crime. Recommended methods for the identification and analysis of cannabis and cannabis products. 2009. Available at: http://www.unodc.org/documents/scientific/ST-NAR-40-Ebook.pdf. Accessed August 4, 2014.
21. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Media, PA: Williams and Wilkins; 1995.
22. Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr. 1990;99:42-62.
23. Fischedick J, Van Der Kobi F, Verpoorte R. Cannabinoid receptor 1 binding activity and quantitative analysis of cannabis sativa smoke and vapor. Chem Pharm Bull. 2010;58:201-207.
24. Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporized Cannabis sativa. Inhal Toxicol. 2009;21:1108-1112.
25. DSouza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahy drocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572.
26. Hunault CC, Mensinga TT, de Vries I, et al. Delta-9- tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl). 2008;201:171-181
27. Hunault CC, van Eijkeren JC, Mensinga TT, et al. Disposition of smoked cannabis with high δ9-tetrahydrocannabinol content: A kinetic model. Toxicol Appl Pharmacol. 2010;246:148-153.
28. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992;52:31-41.
29. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and psychological effects and whole blood δ9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol. 2012;36:405-412.
30. Desrosiers NA,Himes SK, ScheidweilerKB, et al. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60:631-643.
31. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoids-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90:844-851.
32. Lile JA, Kelly TH, Charnigo RJ, Stinchcomb AL, Hays LR. Pharmacokinetic and pharmacodynamic profile of superatherapeutic oral doses of δ9-tetrahydrocannabinol in cannabis users. J Clin Pharmacol. 2013;53:680-690.